Purevax Rabies

RSS

rabies recombinant canarypox virus (vCP65)

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 04/12/2015

Authorisation details

Product details
Name
Purevax Rabies
Agency product number
EMEA/V/C/002003
Active substance
vCP65 virus
International non-proprietary name (INN) or common name
rabies recombinant canarypox virus (vCP65)
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AD
Publication details
Marketing-authorisation holder
Merial
Revision
3
Date of issue of marketing authorisation valid throughout the European Union
17/02/2011
Contact address
29 avenue Tony Garnier
69007 Lyon
France

Product information

02/12/2015 Purevax Rabies - EMEA/V/C/002003 - R/0004

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection.

Onset of immunity: 4 weeks after the primary vaccination course.

Duration of immunity after primary vaccination: 1 year.

Duration of immunity after revaccination: 3 years.

Assessment history

How useful was this page?

Add your rating